Evelyn Elias1, Joelle Helou2, Liying Zhang1, Patrick Cheung2, Andrea Deabreu1, Laura D'Alimonte2, Perakaa Sethukavalan1, Alexandre Mamedov1, Marlene Cardoso1, Andrew Loblaw3. 1. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Canada. 2. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Canada; Department of Radiation Oncology, University of Toronto, Canada. 3. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Canada; Department of Radiation Oncology, University of Toronto, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Canada. Electronic address: andrew.loblaw@sunnybrook.ca.
Abstract
BACKGROUND AND PURPOSE: Initial results of Stereotactic Ablative Body Radiotherapy (SABR) in the treatment of localized prostate cancer appear promising however long-term quality of life (QOL) outcomes and dosimetric correlates are necessary. MATERIAL AND METHODS: A phase I/II study was performed where low risk prostate cancer patients received SABR 35 Gy in 5 fractions, once weekly. Patient self-reported QOL was measured using the Expanded Prostate Cancer Index Composite (EPIC) at baseline and q6 month up to 5 years. Urinary, bowel and sexual domains were analyzed. A minimally clinical important change (MCIC) was defined as 0.5∗standard deviation of the baseline. Univariate and multivariate logistic regression were used to identify dosimetric predictors of MCIC. RESULTS: 84 patients were included. The median follow-up was 50.8 months (interquartile range [IQR], 44.7-56.3). 17.9%, 26.2% and 37.5% of patients reported worse QOL on follow up in the urinary, bowel and sexual domains respectively. On univariate analysis Rectal V31.8>10%, D1cc>35 Gy were associated with bowel MCIC, penile bulb (PB) V35>4%, V20>40% with sexual MCIC. Of these factors only rectal D1cc and PB V35 were predictors of worse QOL on multivariate analysis. CONCLUSIONS: Long-term single-institution QOL outcomes are encouraging. Rigorous dosimetric constraints are needed to keep bothersome side effects low.
BACKGROUND AND PURPOSE: Initial results of Stereotactic Ablative Body Radiotherapy (SABR) in the treatment of localized prostate cancer appear promising however long-term quality of life (QOL) outcomes and dosimetric correlates are necessary. MATERIAL AND METHODS: A phase I/II study was performed where low risk prostate cancerpatients received SABR 35 Gy in 5 fractions, once weekly. Patient self-reported QOL was measured using the Expanded Prostate Cancer Index Composite (EPIC) at baseline and q6 month up to 5 years. Urinary, bowel and sexual domains were analyzed. A minimally clinical important change (MCIC) was defined as 0.5∗standard deviation of the baseline. Univariate and multivariate logistic regression were used to identify dosimetric predictors of MCIC. RESULTS: 84 patients were included. The median follow-up was 50.8 months (interquartile range [IQR], 44.7-56.3). 17.9%, 26.2% and 37.5% of patients reported worse QOL on follow up in the urinary, bowel and sexual domains respectively. On univariate analysis Rectal V31.8>10%, D1cc>35 Gy were associated with bowel MCIC, penile bulb (PB) V35>4%, V20>40% with sexual MCIC. Of these factors only rectal D1cc and PB V35 were predictors of worse QOL on multivariate analysis. CONCLUSIONS: Long-term single-institution QOL outcomes are encouraging. Rigorous dosimetric constraints are needed to keep bothersome side effects low.
Authors: Scott C Morgan; Karen Hoffman; D Andrew Loblaw; Mark K Buyyounouski; Caroline Patton; Daniel Barocas; Soren Bentzen; Michael Chang; Jason Efstathiou; Patrick Greany; Per Halvorsen; Bridget F Koontz; Colleen Lawton; C Marc Leyrer; Daniel Lin; Michael Ray; Howard Sandler Journal: J Clin Oncol Date: 2018-10-11 Impact factor: 44.544
Authors: Thomas P Kole; Michael Tong; Binbin Wu; Siyuan Lei; Olusola Obayomi-Davies; Leonard N Chen; Simeng Suy; Anatoly Dritschilo; Ellen Yorke; Sean P Collins Journal: Acta Oncol Date: 2015-05-14 Impact factor: 4.089
Authors: William C Jackson; Jessica Silva; Holly E Hartman; Robert T Dess; Amar U Kishan; Whitney H Beeler; Laila A Gharzai; Elizabeth M Jaworski; Rohit Mehra; Jason W D Hearn; Todd M Morgan; Simpa S Salami; Matthew R Cooperberg; Brandon A Mahal; Payal D Soni; Samuel Kaffenberger; Paul L Nguyen; Neil Desai; Felix Y Feng; Zachary S Zumsteg; Daniel E Spratt Journal: Int J Radiat Oncol Biol Phys Date: 2019-04-06 Impact factor: 7.038
Authors: Kyle Wang; Panayiotis Mavroidis; Trevor J Royce; Aaron D Falchook; Sean P Collins; Stephen Sapareto; Nathan C Sheets; Donald B Fuller; Issam El Naqa; Ellen Yorke; Jimm Grimm; Andrew Jackson; Ronald C Chen Journal: Int J Radiat Oncol Biol Phys Date: 2020-12-22 Impact factor: 7.038
Authors: Gargi Kothari; Andrew Loblaw; Alison C Tree; Nicholas J van As; Drew Moghanaki; Simon S Lo; Piet Ost; Shankar Siva Journal: Technol Cancer Res Treat Date: 2018-01-01
Authors: Mariska D den Hartogh; Hans C J de Boer; Eline N de Groot-van Breugel; Jochem R N van der Voort van Zyp; Jochem Hes; Uulke A van der Heide; Floris Pos; Karin Haustermans; Tom Depuydt; Robert Jan Smeenk; Martina Kunze-Busch; Bas W Raaymakers; Linda G W Kerkmeijer Journal: Phys Imaging Radiat Oncol Date: 2019-07-15